GHK-Cu, BPC-157, TB-500 and KPV blend (80 mg)
This is the largest of the common peptide blends: four peptides freeze-dried together in one 80 mg vial, most of it GHK-Cu. Each ingredient has been studied a little on its own, mostly in animals or on skin. The four together have never been studied at all. Sellers often call it 'KLOW'; the name is a market nickname, not an ingredient list, and the same name can mean different contents.
As sold, one vial: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. Statuses as of October 3, 2026. Reviewed by the Grey Peptides Editorial Board. Nothing here is a recommendation or a dose, and no seller is named or linked.
Each component at a glance
From our encyclopedia and FDA's July 2026 Pharmacy Compounding Advisory Committee record. Evidence grades follow the rubric on our methodology page.
| Component | Evidence | FDA status | PCAC, July 2026 | WADA 2026 | WADA 2027 | Interactions |
|---|---|---|---|---|---|---|
| GHK-Cu | Low | Research Chemical | Not voted on | Prohibited under S0 (not named) | Prohibited under S0 (not named) | Not yet reviewed |
| BPC-157 | Low | Research Chemical | Recommended (8-6, July 23, 2026); FDA has not acted | Prohibited (S0) | Prohibited (S0) | Partly reviewed |
| TB-500 | Low | Research Chemical | Recommended (8-6, July 23, 2026); FDA has not acted | Prohibited (S2.3) | Prohibited (S2.3) | Partly reviewed |
| KPV | Low | Research Chemical | Recommended (8-6, July 23, 2026); FDA has not acted | Prohibited under S0 (not named) | Prohibited under S0 (not named) | Not yet reviewed |
What one vial contains: the ratio arithmetic
The vial holds 80 mg in total. Whatever volume of water is added and however much is drawn, every draw carries the components in the same proportions. The table expresses each as a share of the vial, as a multiple of the smallest component (BPC-157), and as a concentration if the whole vial were dissolved in 2 mL or 3 mL of water. These are arithmetic illustrations of what is in the vial, not suggested volumes or doses.
| Component | In the vial | Share | × BPC-157 | In 2 mL | In 3 mL |
|---|---|---|---|---|---|
| GHK-Cu | 50 mg | 62.5% | 5 | 25 mg/mL | 16.67 mg/mL |
| BPC-157 | 10 mg | 12.5% | 1 | 5 mg/mL | 3.33 mg/mL |
| TB-500 | 10 mg | 12.5% | 1 | 5 mg/mL | 3.33 mg/mL |
| KPV | 10 mg | 12.5% | 1 | 5 mg/mL | 3.33 mg/mL |
The Blend & Stack Calculator runs the same arithmetic for any volume and draw, with this composition as a preset (GHK-Cu, BPC-157, TB-500 and KPV, 80 mg (50/10/10/10)).
What is in the vial, as sold
Listings for this blend generally state 50 mg of GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV, which is the composition our calculator models. The Name Decoder's review of listings found at least one that reverses the GHK-Cu and BPC-157 amounts, so the label on any particular vial is the first thing to check. A blend's stated composition is a seller's claim: nothing requires the contents of an unregulated vial to match it, and a certificate of analysis that quantifies only one of the four peptides says nothing about the other three.
GHK-Cu makes up 62.5% of the vial by weight. That proportion shapes everything else on this page, because in a fixed-ratio blend the largest component sets the exposure to it whenever any amount of the others is drawn.
What each ingredient's evidence shows
BPC-157 is a 15-amino-acid fragment of a protein in human gastric juice, studied mostly in rats for tissue repair. The human record is two small reports: a 2025 pilot that gave intravenous BPC-157 to two people and found it tolerated, with no change in the markers tested1, and a 2021 chart review of knee injections at one clinic with no control group2.
TB-500 is a synthetic fragment modelled on thymosin beta-4. No human trial has tested TB-500 as sold. The human studies are of the parent protein: an intravenous safety study in healthy volunteers3 and a European trial of thymosin beta-4 applied to venous leg ulcers4. Neither says anything direct about injecting TB-500.
GHK-Cu is a copper complex of a three-amino-acid peptide, and its human evidence is about skin. In a small trial after laser resurfacing, patients rated their skin quality higher with topical GHK-Cu, although investigator-rated outcomes did not differ between groups5. No human study on our entry tested an injection, which is how blends are used.
KPV is lysine-proline-valine, the last three amino acids of alpha-MSH. Its evidence comes from mice: it reduced inflammation in chemically induced colitis6 and in other mouse models of inflammatory bowel disease7. It has not been tested in people.
Has anyone studied the mix?
No. The only reports of giving any combination of these ingredients involve two of them. A 2026 rat study cut and repaired the Achilles tendon in 32 rats, then gave BPC-157, TB-500, both, or nothing for four weeks; only the TB-500 group showed a significant gain in tendon strength, the combination scored better on one tissue-structure scale, and BPC-157 alone did not reach significance on the overall scores8. The 2021 knee chart review included four patients who had separate injections of BPC-157 and thymosin beta-42. Neither tested GHK-Cu or KPV, and neither used a fixed-ratio vial.
That leaves the questions a combination study would answer with no answer at all: whether the four interact with each other, whether one changes how another is absorbed or cleared, whether side effects add up, and whether the peptides stay stable when dissolved and stored together. We found no published data on the stability of these peptides mixed in one vial.
The fixed-ratio problem, for this blend
With five times as much GHK-Cu as each of the other three, any amount drawn to deliver a chosen quantity of BPC-157 also delivers five times that quantity of GHK-Cu, plus equal amounts of TB-500 and KPV. There is no way to take more of one ingredient without taking more of all four, or to stop one while continuing the others. If a reaction happens, a four-way blend makes it impossible to tell which ingredient caused it. These are properties of the vial, not of any particular use, and they are why separate, labelled products are easier to reason about than a mix.
Regulatory status in the United States
None of the four is approved by FDA for any use. In July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157, TB-500 and KPV to the list of substances pharmacies may use in compounding, against the advice of FDA's own reviewers9. A recommendation is not a decision: as of October 3, 2026, FDA had not acted on it, and until it does, pharmacies cannot lawfully compound them. Injectable GHK-Cu cannot be compounded either; its nomination was withdrawn in April 2026, and FDA intends to take GHK-Cu to a second committee meeting before the end of February 202710. Even if every vote were adopted, compounding rules apply to individual substances for individual patients, not to a pre-mixed four-peptide vial sold online. Our regulatory tracker follows each substance.
For tested athletes
All four ingredients are prohibited at all times under the World Anti-Doping Code. BPC-157 is named under S0, non-approved substances, and TB-500 under S211. GHK-Cu and KPV are not named, but as substances with no current approval for human therapeutic use they fall under the S0 catch-all, which covers any pharmacological substance not addressed elsewhere on the List and not approved for human use11. A positive test for any one of them is an anti-doping rule violation, and athletes are strictly liable for what is in a product they take, including an ingredient they did not know was there.
Questions to ask about any vial like this
The Name Decoder's questions for this blend are the ones that matter most. What are the milligrams of each of the four, and do they match the label? Does the certificate of analysis quantify all four peptides by name, with purity for each, or only one? Is the testing laboratory identified, and is the report tied to the batch in hand? Our COA Decoder explains what a genuine report contains and the red flags of a fake one, and our guide to spotting a fake certificate walks through a worked example.
The deeper question is whether a mix is needed at all. A blend combines four ingredients with different, thin evidence bases into one product that cannot be adjusted. Anyone considering it should discuss it with a clinician who knows what they are taking.
Sources
- Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31. PubMed 40131143 ↗
- Lee, E., et al. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 27. PubMed 34324435 ↗
- Ruff, D., et al. (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci, 1194. PubMed 20536472 ↗
- Guarnera, G., et al. (2007). Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci, 1112. PubMed 17495250 ↗
- Miller, T. R., et al. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 8. PubMed 16847171 ↗
- Dalmasso, G., et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134. PubMed 18061177 ↗
- Kannengiesser, K., et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis, 14. PubMed 18092346 ↗
- Biçer, O., et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 37. PubMed 42542926 ↗
- U.S. Food and Drug Administration. July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee: votes on BPC-157, KPV and TB-500 (8 yes, 6 no, 1 abstain). Page current as of August 6, 2026; re-read October 3, 2026. Source ↗
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories (GHK-Cu, injectable nomination withdrawn; non-injectable in Category 1). Updated May 14, 2026; re-read September 26, 2026. Source ↗
- World Anti-Doping Agency. The 2026 Prohibited List (S0 non-approved substances; S2 peptide hormones, growth factors and related substances), in force January 1 to December 31, 2026; the 2027 List keeps the same statuses for these four. Read in full July 16, 2026. Source ↗
Related: the blends and stacks hub, the Name Decoder, the COA Decoder and the Interaction Matrix. Last updated October 3, 2026.